Pharmacotherapy for Cardiovascular Disorders: Case Analysis
This paper presents a case study analysis of a patient diagnosed with hypertension and hyperlipidemia who also has a history of obesity. The paper examines a five-drug regimen — atenolol, doxazosin, hydralazine, sertraline, and simvastatin — evaluating each drug's mechanism of action, dosing parameters, and therapeutic appropriateness. A central focus is placed on how ethnicity influences pharmacokinetic and pharmacodynamic processes, particularly the higher prevalence of arterial hypertension among African Americans and their differential responses to certain drug classes. The paper concludes with clinical recommendations to optimize the patient's treatment plan, including dosage adjustments and combination therapy strategies.
- Introduction and Patient Overview: Patient background: hypertension, hyperlipidemia, obesity
- Current Drug Regimen and Dosing Analysis: Five-drug regimen mechanisms, dosing, and limits
- Ethnicity as a Pharmacokinetic and Pharmacodynamic Factor: Ethnicity's role in hypertension and drug response
- Clinical Recommendations and Lifestyle Modifications: Dosage adjustments, combination therapy, lifestyle changes
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each drug in the regimen is evaluated systematically, covering mechanism of action, dosing range, and the patient's current dose relative to established therapeutic limits.
- The paper integrates ethnicity as a clinically relevant variable, citing peer-reviewed literature to support race-based pharmacological considerations rather than treating the patient generically.
- Recommendations are grounded in the analysis presented earlier, creating a logical progression from assessment to clinical action.
Key academic technique demonstrated
The paper demonstrates applied pharmacological reasoning — moving from drug-specific pharmacokinetics and pharmacodynamics to patient-specific factors such as ethnicity, and ultimately synthesizing this into actionable clinical recommendations. This mirrors the structure of a clinical decision-making framework used in advanced nursing and pharmacy practice.
Structure breakdown
The paper opens with a brief patient introduction, then systematically analyzes each of the five prescribed medications. It transitions to a focused discussion of ethnicity's influence on treatment response, drawing on literature about hypertension in African Americans. The paper closes with specific dosage and lifestyle recommendations. The structure is concise and case-driven, suited to a graduate-level pharmacology course.
Introduction and Patient Overview
This case study examines a patient diagnosed with hypertension and hyperlipidemia. In addition to a history of obesity, the patient has gained approximately nine pounds recently. She has been prescribed five medications, each of which is analyzed below with respect to mechanism of action, dosing parameters, and therapeutic appropriateness.
Current Drug Regimen and Dosing Analysis
Atenolol 12.5 mg daily. As a beta blocker, atenolol affects the patient's cardiovascular circulation and heart function. Administered orally, its absorption is rapid; at doses between 100 mg and the maximum, systolic pressure reduction can be achieved in under one hour. The maximum allowable daily dose is 200 mg, which means the patient's current dose is substantially minimized relative to therapeutic ceilings.
Doxazosin 8 mg daily. The patient has been prescribed the maximum daily dose of this alpha-adrenergic blocker. Doxazosin functions by relaxing the arteries and veins. One rationale for prescribing the maximum dosage may be to treat benign prostatic hyperplasia in addition to managing hypertension.
Hydralazine 10 mg four times daily (qid). A peripheral arterial vasodilator, hydralazine's usual starting dose is 10 mg qid, and the maximum daily dose should not exceed 300 mg. It is important to note that among uremic patients, the elimination rate of hydralazine is significantly slower, which can often be attributed to impaired hepatic metabolism.
Sertraline 25 mg daily. A selective serotonin reuptake inhibitor (SSRI), sertraline is used in the treatment of depression. It facilitates and promotes serotonergic transmission (Burton, Shaw, Schentag, & Evans, 2006), a property that underlies its antidepressant effects. The maximum dose within a 24-hour period is 200 mg, placing the patient well within safe dosing limits. Notably, "depression, a common disease among the adult population, is also accepted as a risk factor for cardiovascular diseases" (Kesim, Tiryaki, Kidioglu, Muci, Kalyoncu, & Yaris, 2011, p. 1525).
Simvastatin 80 mg daily. Simvastatin is, in the words of Burton et al. (2006), "an oral antilipemic agent which inhibits HMG-CoA reductase." The patient has been prescribed double the usual starting dose, which is typically lower than 40 mg daily. This elevated dose warrants monitoring given the increased risk of adverse effects, including myopathy, at higher doses.
Ethnicity as a Pharmacokinetic and Pharmacodynamic Factor
One key factor considered in assessing the influence on the patient's pharmacokinetic and pharmacodynamic processes is ethnicity. Ethnicity is one of several pharmacological variables on this front — others include age, gender, and genetic factors. As Ortega, Sedki, and Nayer (2015) note, "arterial hypertension is prevalent in the black population in the United States" (p. 140). The pathogenesis of this condition comprises a "high incidence of obesity, salt sensitivity, and the activation of the renin-angiotensin aldosterone system" (Ortega, Sedki, & Nayer, 2015, p. 140).
It is also important to note that African Americans tend to have lower circulating renin levels, and their response to calcium channel blockers as well as diuretics appears to be more favorable than their response to some other antihypertensive drug classes. These biological and population-level differences carry meaningful implications for individualized treatment planning.
References
Burton, M. E., Shaw, L. M., Schentag, J. J., & Evans, W. E. (2006). Applied pharmacokinetics & pharmacodynamics: Principles of therapeutic drug monitoring. Lippincott Williams & Wilkins.
Kesim, M., Tiryaki, A., Kidioglu, M., Muci, E., Kalyoncu, N. I., & Yaris, E. (2011). The effects of sertraline on blood lipids, glucose, insulin and HbA1C levels: A prospective clinical trial on depressive patients. Journal of Research in Medical Sciences, 16(12), 1523–1531.
Ortega, L. M., Sedki, E., & Nayer, A. (2015). Hypertension in the African American population: A succinct look at its epidemiology, pathogenesis, and therapy. Nefrologia, 35(2), 139–145.
Create your account
Always verify citation format against your institution’s current style guide requirements.